CN113575934A - Total-nutrient compound protein powder for tumor patients - Google Patents

Total-nutrient compound protein powder for tumor patients Download PDF

Info

Publication number
CN113575934A
CN113575934A CN202110884757.1A CN202110884757A CN113575934A CN 113575934 A CN113575934 A CN 113575934A CN 202110884757 A CN202110884757 A CN 202110884757A CN 113575934 A CN113575934 A CN 113575934A
Authority
CN
China
Prior art keywords
powder
vitamin
compound
protein
oil
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202110884757.1A
Other languages
Chinese (zh)
Inventor
吴洪宾
宋站立
张振中
刘云超
蔺丽丽
马景丽
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shandong Harvey Pharmaceutical Co ltd
Original Assignee
Shandong Harvey Pharmaceutical Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shandong Harvey Pharmaceutical Co ltd filed Critical Shandong Harvey Pharmaceutical Co ltd
Priority to CN202110884757.1A priority Critical patent/CN113575934A/en
Publication of CN113575934A publication Critical patent/CN113575934A/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12—Fatty acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15—Vitamins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15—Vitamins
    • A23L33/155—Vitamins A or D
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/16—Inorganic salts, minerals or trace elements
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/175—Amino acids
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/18—Peptides; Protein hydrolysates
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/19—Dairy proteins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
    • A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Mycology (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Pediatric Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The invention discloses total nutrient compound protein powder for tumor patients, which comprises the following components: the composition consists of the following components: comprises concentrated whey protein, powdered oil, vegetable fat powder, maltodextrin, crystalline fructose, L-glutamine, soybean peptide powder, tuckahoe powder, compound mineral substances, L-leucine, potassium citrate, fish oil powder, inulin, fructo-oligosaccharide and compound vitamins; the compound protein powder has sufficient energy and a high-energy, high-fat and high-protein formula, and is suitable for the nutritional requirements of patients with high energy metabolism; the immune nutrition is added with special nutrient substances with immune regulation function such as glutamine, leucine, omega-3 fatty acid (EPA) and the like, so that the immune nutrition can effectively help patients to enhance immunity, relieve inflammatory reaction of organisms and improve treatment tolerance; the double prebiotics are added with inulin and fructo-oligosaccharide, so that the intestinal health is better maintained; the product can be used as both medicine and food, and has effects of treating anorexia and inhibiting tumor.

Description

Total-nutrient compound protein powder for tumor patients
Technical Field
The invention relates to the technical field of food production, in particular to total nutrient composite protein powder for tumor patients.
Background
The formula food for special medical application is specially processed and prepared for meeting the special requirements of people with limited food intake, digestive absorption disorder, metabolic disorder or specific disease states on nutrients or diet. The product must be eaten alone or in combination with other foods under the guidance of doctors or clinical dieticians. The formula food for special medical application is only one way of providing nutrition support for clinical patients, and provides a selection mode for clinical nutrition support.
Tumors are a genetic disorder, but are not inherited. It means that under the action of tumorigenic factors, the gene of the cell is changed, and the normal regulation and control of the growth of the cell are lost, so that abnormal hyperplasia is caused. Can be divided into two categories, benign and malignant tumors. The former has slow growth, clear boundary with surrounding tissues, no transfer and little harm to human health. The latter grows rapidly, can be transferred to other parts of the body, can also produce harmful substances, damage normal organ structures, cause organism dysfunction and threaten life.
Tumors become common diseases in China and the first cause of death of residents in China. The research on the correlation between the nutrition status of common malignant tumors and the clinical outcome, INSCOC, of the professional committee on tumor nutrition and support treatment of the Chinese anticancer Association is found as follows: 67 percent of hospitalized tumor patients in China have moderate and severe malnutrition. The skeletal muscle protein of the tumor patients is lost rapidly, a part of decomposed muscle protein is taken by the tumor, the rest of the decomposed muscle protein is used as gluconeogenesis precursor or is used for liver to synthesize acute phase protein, the treatment tolerance of the patients is reduced, the treatment effect is reduced, the life quality is reduced, the survival time is shortened, the complication is increased, 20 percent of the tumor patients directly die of malnutrition due to multiple reasons, and the important reason is that the medicine treatment is emphasized and the nutrition treatment is neglected. By improving the nutritional status of patients, the balance of various nutritional components required by human body is maintained, and the survival and life quality of patients can be improved.
Patients with tumors are more prone to malnutrition, with a higher proportion of malnutrition. Malnourished tumor patients have reduced tolerance to radiation, chemotherapy, and surgery, and reduced sensitivity to the anti-therapeutic response. The malnutrition of tumor patients has more complications and shorter survival time. Therefore, the tumor patients need nutrition treatment, and the nutrition treatment has significance for the tumor patients.
Disclosure of Invention
In order to make the technical problems, technical solutions and advantageous effects to be solved by the present invention more apparent, the present invention is further described in detail below with reference to the following embodiments. It should be understood that the specific embodiments described herein are merely illustrative of the invention and are not intended to limit the invention.
In order to achieve the purpose, the invention provides the following technical scheme: a total nutrient compound protein powder for tumor patients comprises the following components: comprises concentrated whey protein, powdered oil, vegetable fat powder, maltodextrin, crystalline fructose, L-glutamine, soybean peptide powder, tuckahoe powder, compound mineral substances, L-leucine, potassium citrate, fish oil powder, inulin, fructo-oligosaccharide and compound vitamins.
Preferably, the compound protein powder comprises the following components in percentage by weight: 20-40% of concentrated whey protein, 10-14% of powdered oil, 20-30% of vegetable fat powder, 9-12% of maltodextrin, 5-8% of crystalline fructose, 1-3% of L-glutamine, 5-8% of soybean peptide powder, 1-4% of tuckahoe powder, 1-3% of compound mineral, 0.1-3% of L-leucine, 0.1-2% of potassium citrate, 0.1-2% of fish oil powder, 0.1-2% of inulin, 0.1-2% of fructo-oligosaccharide and 0.1-2% of compound vitamin.
Preferably, the specific mixture ratio of the compound protein powder is as follows: 30% of concentrated whey protein, 12% of powdered oil, 25% of vegetable fat powder, 10.9% of maltodextrin, 6% of crystalline fructose, 2% of L-glutamine, 6% of soybean peptide powder, 3% of tuckahoe powder, 1.3% of compound mineral, 1% of L-leucine, 0.8% of potassium citrate, 0.6% of fish oil powder, 0.5% of inulin, 0.5% of fructo-oligosaccharide and 0.4% of compound vitamin.
Preferably, the powdered oil comprises one or more of medium chain triglyceride, resistant dextrin, sodium caseinate, mono-diglycerol fatty acid ester and dipotassium hydrogen phosphate.
Preferably, the vegetable fat powder comprises one or more of vegetable oil, glucose syrup, sodium caseinate, mono-diglycerol fatty acid ester and dipotassium hydrogen phosphate.
Preferably, the vegetable oil comprises one or more of soybean oil, coconut oil, sunflower seed oil.
Preferably, the compound mineral comprises one or more of calcium carbonate, magnesium oxide, zinc gluconate, ferric pyrophosphate and maltodextrin.
Preferably, the fish oil powder comprises one or more of refined fish oil, glucose syrup, milk protein, sodium ascorbate, sodium citrate, and mono-diglycerol fatty acid ester.
Preferably, the compound vitamin comprises one or more of L-ascorbic acid, taurine, dl-alpha-tocopherol acetate, nicotinamide, riboflavin, retinyl acetate, calcium pantothenate, folic acid, pyridoxine hydrochloride, thiamine hydrochloride, cholecalciferol, cyanocobalamin and maltodextrin.
Preferably, each 100g of the compound protein powder comprises: 2037kJ energy, 34.0g protein, 25.7g fat, 33.9g carbohydrate, 3.4g dietary fiber, 495mg sodium, 500. mu.g RE vitamin A, 1.12mg vitamin B1, 1.12mg vitamin B2, 1.12mg vitamin B6, 1.80mg vitamin B12, 125.0mg vitamin C, 1.5. mu.g vitamin D, 9mg alpha-TE vitamin E, 15.0mg niacin, 200. mu.g folic acid, 5.0mg pantothenic acid, 162mg magnesium, 350mg calcium, 12.0mg iron, 9.00mg zinc, 110mg taurine.
Theoretical basis for formula selection
Soybean peptide powder
The nutritional value of soy protein is very close to that of meat protein, and soy has been used as a cheap substitute for meat, namely 'vegetable meat'. However, recent studies have confirmed that soy protein has health-care value not possessed by meat proteins. The product obtained by the enzymolysis of the soybean protein, namely the soybean peptide, is a bioactive polypeptide, can be used as a protein source, has extremely strong physiological activity, and has various physiological functions of resisting fatigue, preventing radiation, reducing blood pressure, reducing blood fat, promoting fat metabolism and the like. Epidemiological investigation shows that the soybean product can prevent and treat tumor. The soybean protein isolate in the food, i.e., soybean peptide, inhibits the growth of human prostate cancer cells. The soybean peptide can obviously reduce the tumor amplification. Increase apoptosis and decrease microtubule density. The anti-tumor effect of soybean peptide is achieved by inhibiting tumor metastasis and growth, selectively killing tumor cells and enhancing the non-specific immune function of the body.
Inulin and fructo-oligosaccharide
Inulin and fructo-oligosaccharide are used as functional food raw materials, and have dual effects of dietary fiber and prebiotics.
Inulin can be hydrolyzed into fructose or fructo-oligosaccharide, and the influence of inulin on human health is similar to that of fructo-oligosaccharide; (1) can proliferate Bacillus bifidus in intestinal tract, and prevent intestinal infection; (2) controlling blood fat, reducing the harm of cardiovascular diseases and the like, inulin serving as dietary fiber can absorb intestinal fat to form a fat-fiber compound to be discharged along with excrement, and is beneficial to reducing the blood fat level; (3) the dietary fiber in daily diet can reduce the absorption of certain minerals by intestinal tracts, and any inulin-mineral complex can be degraded in the fermentation process of intestinal flora to release mineral elements, so that the inulin-mineral complex is more beneficial to the absorption of the intestinal tracts; (4) the inulin is supplemented every day according to the recommended dose in diet for preventing and treating constipation, so that the defecation frequency of patients with constipation can be remarkably increased, and the stool becomes soft and coherent; (5) in addition, inulin is nontoxic, can not be synthesized or decomposed in vivo, is completely filtered by glomeruli after being injected into a human body through veins, is not reabsorbed or secreted by renal tubules, and can be used for measuring the glomerular filtration rate in medicine; the results of the existing preliminary animal experiments prove that the inulin can prevent intestinal canceration and enhance the immunity of the organism.
The fructo-oligosaccharide is a water-soluble dietary fiber, and can improve intestinal flora balance, improve lipid metabolism, and promote mineral element absorption. Fructooligosaccharides are found to have excellent physiological properties: (1) the bifidobacterium can be selectively utilized in the large intestine, and the number of the bifidobacterium in the body can be increased by 100-1000 times after fructo-oligosaccharide is taken; (2) is difficult to be hydrolyzed by human digestive tract salivary enzyme and small intestine digestive enzyme, and is a low calorie sugar; (3) can be regarded as a water-soluble dietary fiber, can reduce blood fat, improve lipid metabolism, after the patient takes, its cholesterol, triglyceride, free fatty acid are all reduced; (4) inhibiting growth of Salmonella and putrefying bacteria in intestine, and promoting gastrointestinal function.
Omega-3 fatty acids (EPA), L-glutamine, L-leucine
Research shows that EPA and DHA can effectively inhibit the generation, growth and metastasis speed of tumors. In addition, EPA and DHA both contain multiple double bonds and are natural products of lipid peroxidation. The active oxygen generated by lipid peroxide can improve the sensitivity of tumor cells to therapeutic drugs, and the generated free radicals and lipid peroxide can inhibit the expression of tumor cells, shorten telomeres of chromosomes and promote the apoptosis of tumor cells.
Glutamine can slow down tumor growth by stimulating the body's immune system. In addition, glutamine can reduce the concentration of glutathione in tumor cells, thereby enhancing the sensitivity of the tumor cells to radiotherapy and chemotherapy and effectively enhancing the curative effect of the radiotherapy and the chemotherapy. Meanwhile, exogenous glutamine is supplemented to restore the glutathione level reduced by normal host cells to normal, thereby improving the host condition and reducing the incidence rate and death rate of complications related to tumors and treatment thereof. Omega-3 polyunsaturated fatty acid and glutamine have the effect of improving the cellular immunity level of the organism, and can also exert stronger synergistic effect when used together. And the parenteral nutrition effect of the combination of omega-3 polyunsaturated fatty acid and glutamine is obviously superior to that of monoglutamine. Leucine can promote muscle synthesis and relieve weight loss of tumor patients.
Action of vitamins and minerals on tumors
Vitamin A
With the clinical research of vitamin A, it has certain prevention and cure effect on malignant tumor. The vitamin A compound can control cell proliferation and differentiation, inhibit tumor cell growth, and promote differentiation.
Vitamin C, vitamin E and selenium
The supplement of micronutrients, especially antioxidants, is very important and has a number of effects, including improving tumour-related anorexia, reducing treatment-related adverse reactions, improving the treatment effect and quality of life, and preventing tumour recurrence. Therefore, sufficient antioxidants (such as vitamin C, vitamin E, selenium and the like) with the daily recommended intake amount of 1-3 times are used before, during and after the tumor treatment.
The action mechanism of selenium is deeply researched in the aspects of antioxidation, immunity improvement, tumor energy metabolism limitation and the like of a body. It has been reported that mitochondria within tumor cells may be one of the major sites of selenium action; selenium has also been reported to selectively block oxidative phosphorylation in cancer cells or to directly inhibit the synthesis of DNA, RNA and proteins in cancer cells, thereby inhibiting the proliferation of cancer cells.
Vitamin K
The research shows that the tumor of the tumor patient receiving the vitamin K treatment has necrosis phenomenon, so that the vitamin K also has the anti-tumor effect. Antagonize the procoagulant effect of vitamin K, and can inhibit the growth and metastasis of tumor cells; the use of anticoagulants, and the resulting vitamin K deficiency, can reduce fibrin clot formation, making tumor cells difficult to survive, and their metastatic potential can be limited as a result. The relation between vitamin K analogues and tumors is complex, and the vitamin K analogues are related to tumor metastasis or bacterial mutation, or can be used as a cytotoxic drug for treating tumors or as a chemotherapeutic sensitizer for reducing the dosage and toxicity of chemotherapeutic drugs. The anti-tumor action mechanism is very complex, and free radicals, especially oxygen free radicals, are closely related to the toxicity and the curative effect of vitamin K.
Sodium salt
Hyponatremia is a clinically common electrolyte disorder, reflecting a relative or absolute decrease in the total amount of Na + in plasma. The hyponatremia of tumor patients can be caused by the influence of the biological activity of the tumor, the antitumor drug, the iatrogenic source and other factors. It is often manifested as nonspecific symptoms such as fatigue, nausea, vomiting, etc., and in severe cases, mental symptoms or even death may occur due to encephaledema. Therefore, hyponatremia associated with tumors should be considered and treated in time.
Potassium salt
Potassium is a main cation for maintaining cell metabolism and functions, slight change of potassium ions outside cells can generate great influence on organisms, and the slight change of potassium ions can interfere with the maintenance of muscle excitability, cell distribution structure and acid-base balance of body fluid. Hypokalemia often appears in patients with advanced tumor, and the conventional intravenous potassium supplement inputs a large amount of liquid to cause blood volume increase, kidney load aggravation and tissue edema aggravation.
Manganese oxide
The action of manganese on tumors is not uniform, and people think that the body can be carcinogenic due to manganese deficiency, but people think that the body can be carcinogenic due to manganese deficiency.
Taurine
Taurine is indispensable amino acid for human, and has the wide biological effects of maintaining normal visual function, maintaining the osmotic pressure balance of the organism, maintaining the stability of cell membranes, reducing blood sugar, protecting tissue ischemia reperfusion injury, improving the immunity of the organism, regulating lipid secretion, protecting cardiac muscle cells, resisting oxidation, resisting tumors and the like.
Taurine can enhance the curative effect of the anti-tumor medicine and reduce the adverse reaction of the anti-tumor medicine by enhancing the immunity of the organism and influencing the cell intake and discharge of the anti-tumor medicine; taurine inhibits tumor growth by improving the body's antioxidant capacity; taurine plays a role in immunological rejection to tumors by enhancing the immunity of the organism; taurine inhibits tumor growth by inducing apoptosis of tumor cells; in addition, taurine also inhibits tumor growth by other pathways: taurine can inhibit potential infiltration and metastasis of glioma SHG44 cells caused by ionizing radiation by down-regulating the expression of matrix metalloproteinase 2 and up-regulating the expression of N-acetylgalactosamine transferase 2; the taurine has the capability of improving the DNA damage repair of organisms, and can reduce the level of a dimethylbenzene anthracene-induced breast cancer rat plasma DNA damage metabolite O6-methylguanine.
Has the advantages that: compared with the prior art, the invention has the beneficial effects that:
1. the formula has sufficient energy and high energy, high fat and high protein, and is suitable for the nutritional requirements of patients with high energy metabolism;
2. high-quality protein, high-quality soybean peptide powder is selected as protein supplement, essential amino acid is rich, the digestion and absorption are easy, and a nitrogen source is rapidly supplemented;
3. the immune nutrition is added with special nutrient substances with immune regulation function such as glutamine, leucine, omega-3 fatty acid (EPA) and the like, so that the immune nutrition can effectively help patients to enhance immunity, relieve inflammatory reaction of organisms and improve treatment tolerance;
4. various antioxidants, vitamin C, vitamin E, selenium and the like can improve anorexia of patients and reduce adverse reactions related to treatment;
5. the double prebiotics are added with inulin and fructo-oligosaccharide, so that the intestinal health is better maintained;
6. the product can be used as both medicine and food, and has effects of treating anorexia and inhibiting tumor.
Detailed Description
The technical solution of the present patent will be described in further detail with reference to the following embodiments.
The invention provides the following technical scheme: a total nutrient compound protein powder for tumor patients comprises the following components: comprises concentrated whey protein, powdered oil, vegetable fat powder, maltodextrin, crystalline fructose, L-glutamine, soybean peptide powder, tuckahoe powder, compound mineral substances, L-leucine, potassium citrate, fish oil powder, inulin, fructo-oligosaccharide and compound vitamins.
Further, the compound protein powder comprises the following components in percentage by weight: 20-40% of concentrated whey protein, 10-14% of powdered oil, 20-30% of vegetable fat powder, 9-12% of maltodextrin, 5-8% of crystalline fructose, 1-3% of L-glutamine, 5-8% of soybean peptide powder, 1-4% of tuckahoe powder, 1-3% of compound mineral, 0.1-3% of L-leucine, 0.1-2% of potassium citrate, 0.1-2% of fish oil powder, 0.1-2% of inulin, 0.1-2% of fructo-oligosaccharide and 0.1-2% of compound vitamin.
Further, the specific mixture ratio of the compound protein powder is as follows: 30% of concentrated whey protein, 12% of powdered oil, 25% of vegetable fat powder, 10.9% of maltodextrin, 6% of crystalline fructose, 2% of L-glutamine, 6% of soybean peptide powder, 3% of tuckahoe powder, 1.3% of compound mineral, 1% of L-leucine, 0.8% of potassium citrate, 0.6% of fish oil powder, 0.5% of inulin, 0.5% of fructo-oligosaccharide and 0.4% of compound vitamin.
Further, the powdered oil and fat comprises one or more of medium chain triglyceride, resistant dextrin, sodium caseinate, mono-diglycerol fatty acid ester and dipotassium hydrogen phosphate.
Further, the vegetable fat powder comprises one or more of vegetable oil, glucose syrup, sodium caseinate, mono-diglycerol fatty acid ester and dipotassium hydrogen phosphate.
Further, the vegetable oil comprises one or more of soybean oil, coconut oil and sunflower seed oil.
Further, the compound mineral comprises one or more of calcium carbonate, magnesium oxide, zinc gluconate, ferric pyrophosphate and maltodextrin.
Further, the fish oil powder comprises one or more of refined fish oil, glucose syrup, milk protein, sodium ascorbate, sodium citrate, and mono-diglycerol fatty acid ester.
Further, the compound vitamin comprises one or more of L-ascorbic acid, taurine, dl-alpha-tocopherol acetate, nicotinamide, riboflavin, retinyl acetate, calcium pantothenate, folic acid, pyridoxine hydrochloride, thiamine hydrochloride, cholecalciferol, cyanocobalamine and maltodextrin.
Furthermore, each 100g of the compound protein powder comprises: 2037kJ energy, 34.0g protein, 25.7g fat, 33.9g carbohydrate, 3.4g dietary fiber, 495mg sodium, 500. mu.g RE vitamin A, 1.12mg vitamin B1, 1.12mg vitamin B2, 1.12mg vitamin B6, 1.80mg vitamin B12, 125.0mg vitamin C, 1.5. mu.g vitamin D, 9mg alpha-TE vitamin E, 15.0mg niacin, 200. mu.g folic acid, 5.0mg pantothenic acid, 162mg magnesium, 350mg calcium, 12.0mg iron, 9.00mg zinc, 110mg taurine.
Example 1
The total-nutrient compound protein powder for the tumor patient in the embodiment comprises the following components in parts by weight: 20% of concentrated whey protein, 10% of powdered oil, 20% of vegetable fat powder, 9% of maltodextrin, 5% of crystalline fructose, 1% of L-glutamine, 5% of soybean peptide powder, 1% of tuckahoe powder, 1% of compound mineral, 0.1% of L-leucine, 0.1% of potassium citrate, 0.1% of fish oil powder, 0.1% of inulin, 0.1% of fructo-oligosaccharide and 0.1% of compound vitamin.
Example 2
The total-nutrient compound protein powder for the tumor patient in the embodiment comprises the following components in parts by weight: 40% of concentrated whey protein, 14% of powdered oil, 30% of vegetable fat powder, 12% of maltodextrin, 8% of crystalline fructose, 3% of L-glutamine, 8% of soybean peptide powder, 4% of tuckahoe powder, 3% of compound mineral, 3% of L-leucine, 2% of potassium citrate, 2% of fish oil powder, 2% of inulin, 2% of fructo-oligosaccharide and 2% of compound vitamin.
Example 3
The total-nutrient compound protein powder for the tumor patient in the embodiment comprises the following components in parts by weight: 30% of concentrated whey protein, 12% of powdered oil, 25% of vegetable fat powder, 10.9% of maltodextrin, 6% of crystalline fructose, 2% of L-glutamine, 6% of soybean peptide powder, 3% of tuckahoe powder, 1.3% of compound mineral, 1% of L-leucine, 0.8% of potassium citrate, 0.6% of fish oil powder, 0.5% of inulin, 0.5% of fructo-oligosaccharide and 0.4% of compound vitamin.
The brewing method comprises the following steps: adding 5 spoons of powder (about 9g per spoon) according to the requirement, pouring a little water (warm water at about 60 ℃) into the powder, fully stirring the mixture, adding water again, stirring the mixture evenly (about 200ml) to obtain the drink, and taking the drink 1-8 times a day.
Note that: 1. the product comprises dairy product, bean product and fish product;
2. the edible amount of the inulin is less than or equal to 15 g/day, the edible amount of the fish oil is less than or equal to 3 g/day, and the edible amount of the product is recommended to be within a safe range.
Storage conditions were as follows: sealing, drying in the shade, and storing at room temperature.
Shelf life: and 24 months.
The compound protein powder has sufficient energy and a high-energy, high-fat and high-protein formula, and is suitable for the nutritional requirements of patients with high energy metabolism; high-quality protein, high-quality soybean peptide powder is selected as protein supplement, essential amino acid is rich, the digestion and absorption are easy, and a nitrogen source is rapidly supplemented; the immune nutrition is added with special nutrient substances with immune regulation function such as glutamine, leucine, omega-3 fatty acid (EPA) and the like, so that the immune nutrition can effectively help patients to enhance immunity, relieve inflammatory reaction of organisms and improve treatment tolerance; various antioxidants, vitamin C, vitamin E, selenium and the like can improve anorexia of patients and reduce adverse reactions related to treatment; the double prebiotics are added with inulin and fructo-oligosaccharide, so that the intestinal health is better maintained; the product can be used as both medicine and food, and has effects of treating anorexia and inhibiting tumor.
The embodiments described above are preferred embodiments of the present invention, and not all embodiments. The detailed description of the embodiments of the present invention is not intended to limit the scope of the invention as claimed, but is merely representative of selected embodiments of the invention. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention.

Claims (10)

1. The total nutrient composite protein powder for tumor patients is characterized by comprising the following components: comprises concentrated whey protein, powdered oil, vegetable fat powder, maltodextrin, crystalline fructose, L-glutamine, soybean peptide powder, tuckahoe powder, compound mineral substances, L-leucine, potassium citrate, fish oil powder, inulin, fructo-oligosaccharide and compound vitamins.
2. The total nutrient composite protein powder for tumor patients according to claim 1, which is characterized in that: the compound protein powder comprises the following components in percentage by weight: 20-40% of concentrated whey protein, 10-14% of powdered oil, 20-30% of vegetable fat powder, 9-12% of maltodextrin, 5-8% of crystalline fructose, 1-3% of L-glutamine, 5-8% of soybean peptide powder, 1-4% of tuckahoe powder, 1-3% of compound mineral, 0.1-3% of L-leucine, 0.1-2% of potassium citrate, 0.1-2% of fish oil powder, 0.1-2% of inulin, 0.1-2% of fructo-oligosaccharide and 0.1-2% of compound vitamin.
3. The total nutrient composite protein powder for tumor patients according to claim 2, which is characterized in that: the specific mixture ratio of the compound protein powder is as follows: 30% of concentrated whey protein, 12% of powdered oil, 25% of vegetable fat powder, 10.9% of maltodextrin, 6% of crystalline fructose, 2% of L-glutamine, 6% of soybean peptide powder, 3% of tuckahoe powder, 1.3% of compound mineral, 1% of L-leucine, 0.8% of potassium citrate, 0.6% of fish oil powder, 0.5% of inulin, 0.5% of fructo-oligosaccharide and 0.4% of compound vitamin.
4. The total nutrient composite protein powder for tumor patients according to claim 1, which is characterized in that: the powdered oil and fat comprises one or more of medium chain triglyceride, resistant dextrin, sodium caseinate, mono-diglycerol fatty acid ester and dipotassium hydrogen phosphate.
5. The total nutrient composite protein powder for tumor patients according to claim 1, which is characterized in that: the vegetable fat powder comprises one or more of vegetable oil, glucose syrup, sodium caseinate, mono-diglycerol fatty acid ester and dipotassium hydrogen phosphate.
6. The total nutrient composite protein powder for tumor patients according to claim 1, which is characterized in that: the vegetable oil comprises one or more of soybean oil, coconut oil and sunflower seed oil.
7. The total nutrient composite protein powder for tumor patients according to claim 1, which is characterized in that: the compound mineral comprises one or more of calcium carbonate, magnesium oxide, zinc gluconate, ferric pyrophosphate and maltodextrin.
8. The total nutrient composite protein powder for tumor patients according to claim 1, which is characterized in that: the fish oil powder comprises one or more of refined fish oil, glucose syrup, milk protein, sodium ascorbate, sodium citrate, and mono-and diglycerol fatty acid ester.
9. The total nutrient composite protein powder for tumor patients according to claim 1, which is characterized in that: the compound vitamin comprises one or more of L-ascorbic acid, taurine, dl-alpha-tocopherol acetate, nicotinamide, riboflavin, retinyl acetate, calcium pantothenate, folic acid, pyridoxine hydrochloride, thiamine hydrochloride, cholecalciferol, cyanocobalamine and maltodextrin.
10. The total nutrient composite protein powder for tumor patients according to claim 3, which is characterized in that: every 100g of the compound protein powder comprises: 2037kJ energy, 34.0g protein, 25.7g fat, 33.9g carbohydrate, 3.4g dietary fiber, 495mg sodium, 500. mu.g RE vitamin A, 1.12mg vitamin B1, 1.12mg vitamin B2, 1.12mg vitamin B6, 1.80mg vitamin B12, 125.0mg vitamin C, 1.5. mu.g vitamin D, 9mg alpha-TE vitamin E, 15.0mg niacin, 200. mu.g folic acid, 5.0mg pantothenic acid, 162mg magnesium, 350mg calcium, 12.0mg iron, 9.00mg zinc, 110mg taurine.
CN202110884757.1A 2021-08-02 2021-08-02 Total-nutrient compound protein powder for tumor patients Pending CN113575934A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202110884757.1A CN113575934A (en) 2021-08-02 2021-08-02 Total-nutrient compound protein powder for tumor patients

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202110884757.1A CN113575934A (en) 2021-08-02 2021-08-02 Total-nutrient compound protein powder for tumor patients

Publications (1)

Publication Number Publication Date
CN113575934A true CN113575934A (en) 2021-11-02

Family

ID=78254135

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202110884757.1A Pending CN113575934A (en) 2021-08-02 2021-08-02 Total-nutrient compound protein powder for tumor patients

Country Status (1)

Country Link
CN (1) CN113575934A (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115088833A (en) * 2022-05-20 2022-09-23 唛迪森营养科技(江苏)有限公司 Functional food for preventing and/or treating intestinal injury of tumor patient
CN115137078A (en) * 2022-05-30 2022-10-04 广州态好生物科技有限公司 Total-nutrient formula food and preparation method and application thereof
CN115251373A (en) * 2022-08-12 2022-11-01 中科爱伽(天津)医用食品有限公司 Special dietary food for controlling weight, preparation process and application thereof
CN115989872A (en) * 2022-12-07 2023-04-21 山东欣希安药业股份有限公司 Composition for improving nutritional status of tumor patient and preparation method thereof
CN116807019A (en) * 2023-07-19 2023-09-29 山东省农业科学院 Composition with effects of inhibiting muscle decomposition and regulating metabolism and its application in improving nutritional status

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108095088A (en) * 2017-12-27 2018-06-01 福格森（武汉）生物科技股份有限公司 Full nutrient formulation powder suitable for tumor patient rehabilitation and preparation method thereof
CN110839884A (en) * 2019-12-04 2020-02-28 上海张新生物医药科技有限公司 Nutritional composition for improving body inflammatory signs of tumor patients and preparation method thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108095088A (en) * 2017-12-27 2018-06-01 福格森（武汉）生物科技股份有限公司 Full nutrient formulation powder suitable for tumor patient rehabilitation and preparation method thereof
CN110839884A (en) * 2019-12-04 2020-02-28 上海张新生物医药科技有限公司 Nutritional composition for improving body inflammatory signs of tumor patients and preparation method thereof

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115088833A (en) * 2022-05-20 2022-09-23 唛迪森营养科技(江苏)有限公司 Functional food for preventing and/or treating intestinal injury of tumor patient
CN115137078A (en) * 2022-05-30 2022-10-04 广州态好生物科技有限公司 Total-nutrient formula food and preparation method and application thereof
CN115251373A (en) * 2022-08-12 2022-11-01 中科爱伽(天津)医用食品有限公司 Special dietary food for controlling weight, preparation process and application thereof
CN115989872A (en) * 2022-12-07 2023-04-21 山东欣希安药业股份有限公司 Composition for improving nutritional status of tumor patient and preparation method thereof
CN116807019A (en) * 2023-07-19 2023-09-29 山东省农业科学院 Composition with effects of inhibiting muscle decomposition and regulating metabolism and its application in improving nutritional status

Similar Documents

Publication Publication Date Title
CN113575934A (en) Total-nutrient compound protein powder for tumor patients
CN106616615A (en) Clinical nutrient formula special for tumor and preparation method of clinical nutrient formula
CN112089051A (en) Nutritional composition for improving body inflammatory signs of tumor patients and preparation method thereof
CN113397164A (en) Special medical full-nutrition formula food for improving immunity and preparation method thereof
CN110720628A (en) Special clinical nutrition formula for protecting chemotherapy-damaged intestinal mucosa barrier function and preparation method thereof
CN111990463A (en) Bovine colostrum composite powder
KR101186898B1 (en) Antioxidative composition
CN105815514A (en) Weight-losing quinoa milk tea
CN108391811A (en) A kind of tumour full nutrition formula food and its application
CN106107463A (en) Super Quinoa Antifatigue milk tea processing technology
CN111436601A (en) Special clinical nutrition formula for pancreatic cancer and preparation thereof
CN101569410A (en) Special meal nutritional foods used by tumor patients
CN113632848A (en) Children milk powder beneficial to bone growth and preparation method thereof
CN101766274B (en) Antioxidant functional food composition containing bamboo-leaves flavones
CN112137115A (en) Ketogenic nutrition powder with immunity enhancing effect and preparation method thereof
CN108719977A (en) A kind of breast cancer nutraceutical and preparation method thereof
CN115997920A (en) Total nutrient medical use formula food for wounded patients
CN110150654A (en) A kind of special medicine purposes formula food for tumor patient
CN111436597B (en) Lipotide and its production process
CN104757535A (en) Lycium ruthenicum slimming tablet (tea)
CN110754656A (en) Special clinical nutrition formula for lymphoma function and preparation method thereof
CN111802633A (en) Special clinical nutrition formula for esophageal cancer and preparation method thereof
CN111513333A (en) Special clinical nutritional formula food for lung cancer and preparation method thereof
CN114868890A (en) Multi-vitamin nutrient formula suitable for tumor patients
CN108371709A (en) Lycium ruthenicum tumor recovering gene enzyme

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20211102